Rhythm Pharmaceuticals announces three data abstracts accepted for ENDO 2025

Rhythm Pharmaceuticals (RYTM) announced that three late-breaking abstracts have been accepted for presentation at The Endocrine Society’s Annual Meetin taking place July 12-15 in San Francisco, CA. In a live oral presentation, Susan Phillips, M.D., Pediatric Endocrinology, University of California San Diego/Rady Children’s Hospital, San Diego, will present data from Rhythm’s pivotal Phase 3 TRANSCEND trial evaluating setmelanotide in the largest randomized, placebo-controlled trial in acquired hypothalamic obesity to date. Christian Roth, M.D., Seattle Children’s Research Institute, will present a poster detailing exit interviews gathered from 30 patients or caregivers located in the US with acquired hypothalamic obesity who participated in the Phase 3 TRANSCEND trial. Vidhu Thaker, M.D., Pediatric Endocrinology, Columbia University, New York City will present a poster from the 14-week, multicenter, international, randomized, double-blind, placebo-controlled Phase 2 trial of bivamelagon, an oral MC4R agonist, in participants with acquired hypothalamic obesity.